Archives: Premium Distribution

SRAX (NASDAQ: SRAX) is a diversified financial technology, digital marketing and consumer data management company that provides an array of consumer data to its clients, valuable to marketing and communications. Its flagship offering is a premier investor intelligence and communications platform branded Sequire. SRAX also recently launched an IR Website Builder, SMS feature and VIRA, and an IR chatbot, expanding its offering and translating to a strong increase in revenue. “SRAX’s technology unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing,” reads a recent article. Sino American Oil Company (OTC: OILY) recently engaged SRAX to better understand its investors and target them in a more efficient manner. The partnership will allow Sino American Oil to optimize marketing and communications strategies to reach out to consumers, shareholders and investors. “According to Sino American Oil CEO Kim Halvorson, the company did its due diligence before partnering with SRAX. ‘We have been following SRAX for some time now, their expertise in the Oil and Gas sector and digital marketing has been impressive,’ said Halvorson.” To view the full article, visit https://ibn.fm/BQcXk About SRAX Inc. SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has provided a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the company for a transformative 2022. “2021 was an exciting year for Cybin. We expanded our organization from five to more than 55 employees across four countries and have established an operating ecosystem of nearly 50 partners and vendors that have supported more than 90 preclinical studies and numerous patent and investigational new drug filings over the past 12 months,” said Cybin’s CEO Doug Drysdale in the news release. “Driven by promising and differentiating preclinical data, our innovative operational and R&D pipeline platforms expect to support four first-in-human clinical studies in 2022, which we hope will progress our proprietary psychedelic development candidates CYB003 and CYB004 closer toward potential approval for treating depression and addiction disorders. We believe 2022 will be a truly transformative year for Cybin.”

To view the full press release, visit https://ibn.fm/Oe2yL

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Patent filings described herein are held by Cybin IRL Limited, a wholly owned subsidiary of Cybin. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. In January 2022, the company expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies that evidenced effective, sustained and safe blood pressure reduction with DehydraTECH-CBD. The company will also be expecting approvals for the protocols around its fourth hypertension study, HYPER-H21-4, which is just one of the many planned studies slated for 2022. “Others include HOR-A22-1, a pharmacokinetic study to evaluate DehydraTECH’s ability to improve the delivery characteristics of estrogen; DEM-A22-1, an efficacy modeling study to evaluate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia; RHEUM-A22-1, an efficacy modeling study to investigate the ability of DehydraTECH-CBD to potentially affect the treatment of rheumatoid disease; and DIAB-A22-1, an efficacy modeling study to explore DehydraTECH-CBD’s ability to potentially impact treatment of diabetes,” explains a recent article. “In addition to fulfilling Lexaria’s goal to enter into new, different multibillion markets, the four animal studies will mark the company’s push to help patients living with these conditions, some of which are potentially fatal.”

To view the full article, visit https://cnw.fm/93Tti

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Electrification is picking up more steam as countries pass increasingly strict tailpipe emission standards and more players join the nascent electric vehicle (“EV”) industry. Furthermore, the electric vehicle game isn’t limited to just EV startups; most established automakers are also working on electrifying their vehicle lineups and surpassing Tesla, which is currently the world’s largest electric vehicle maker. General Motors Company (NYSE: GM) plans to achieve this goal in large by leveraging existing manufacturing facilities and retrofitting them to build electric vehicles. And like fellow automakers, GM will invest a significant amount of money in electrification in the next decade.

According to sources close to the Detroit-based carmaker, GM intends to invest more than $3 billion to manufacture electric vehicles in its home…

Read More >>

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Electric vehicles have one core aspect that makes them extremely superior to combustion engine vehicles: they produce zero emissions at the tailpipe. By eliminating combustion engines and the fossil fuels that power those engines in exchange for rechargeable battery packs, automakers can reduce vehicle emissions by a significant margin. With a large portion of the world looking to cut down greenhouse gas emissions in a bid to arrest runaway climate change, EVs represent the next logical evolution of vehicular transport. However, EV technology is still relatively new, and players in the EV and battery-making spaces are constantly tweaking their formulas and designs to create more energy-dense EV batteries and energy-efficient electric cars.

That’s what makes a recent announcement by California-based EV startup Tesla Inc. (NASDAQ: TSLA) so interesting. In late August, the EV pioneer announced that it was offering an alternate version of the Model 3 Standard Range+ that would allow customers who had preordered the EV to get it sooner. By incorporating new battery chemistry into the Model 3 cars, Tesla could deliver the vehicles…

Read More >>

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, held its general meeting on Dec. 17, 2021, and approved the election of all director nominees. Those elected will hold office until the next annual shareholder meeting or until their successors are elected or appointed. The company also noted that all of the matters outlined for consideration and approval in InMed’s notice of meeting and management information circular were approved. In addition, the company announced that an article discussing cannabinol (“CBN”) as a potential treatment option for glaucoma has been published in a peer-reviewed journal. The article, titled “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma,” was published in the “Biochimica et Biophysical Acta” journal. The article concludes that, first, CBN may promote neuroprotection of cells in the retina that are responsible for vision, and second, the substance may normalize intraocular pressure by attenuating changes in the extracellular matrix proteins. “Having this research peer-reviewed and published in such a reputable journal is a significant milestone for InMed’s glaucoma development program,” said InMed scientific advisor Dr. Mauro Maccarrone in the press release. “This provides important external validation for the scientific community as the program advances towards human studies. We believe InMed’s INM-088 program has significant implications for neuroprotection within the glaucoma space and may lead to a potential new treatment for millions of people suffering from this condition worldwide.”

To view the full press releases, visit https://ibn.fm/OSBUi and https://ibn.fm/7n2wg

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is partnering with Dürr, one of the world’s leading mechanical and plant engineering firms. Durr brings extensive expertise in automation and digitalization to the partnership, which is designed to focus on MULN’s EV manufacturing footprint. According to the agreement, Dürr, which has extensive expertise in automation and digitalization, will support Mullen’s Advanced Manufacturing and Engineering Center (“AMEC”) with full integration for vehicle assembly and complete paint shop technologies; the engineering center is located in Tunica, Mississippi. “Dürr is a leading international manufacturing systems and technology provider for the automotive industry,” said Mullen Automotive CEO and chair David Michery in the press release. “Our Tunica facility will be a leading example of manufacturing automation. Our goal is to have the best and most efficient manufacturing footprint in the U.S., and Dürr is a key partner in achieving this effort.”

To view the full press release, visit https://ibn.fm/feKeA

About Mullen

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

• Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood pressure)
• The company’s studies earlier this year indicated the potential of DehydraTECH to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation
• Arterial stiffness is a noted indicator of diseases such as heart, kidney and pancreas organ ailments that increase mortality with age, therefore the ability to reduce arterial stiffness may have implications for improving human wellness and longevity
• HYPER-H21-2 results evidence DehydraTECH-CBD reduces arterial stiffness

Lexaria Bioscience (NASDAQ: LEXX), an innovator in how drugs are utilized by the human body, is reporting newly found benefits from cannabidiol (“CBD”) enhanced by Lexaria’s patented DehydraTECH(TM) technology. The company’s Dec. 8 news release notes that DehydraTECH-formulated CBD was found to reduce arterial stiffness in mild-to-moderate hypertension (high blood pressure) patients volunteering in Lexaria’s HYPER-H21-2 human clinical study (https://cnw.fm/zIrF2). The company believes… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office [email protected]

Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a psychedelic drug impacts the substance’s effects. Microdosing refers to consuming a small dose of a recreational dose of a psychedelic, the most commonly used substances being psilocybin and LSD.

The biotech firm announced that its research would…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

• Flora Growth’s subsidiary, Vessel Brand, recently introduced new products for dry herb consumption and anticipates releasing additional products in 2022
• FLGC acquired Vessel in a transaction that closed in November
• Founded in 2018, Vessel is an industry leader in the cannabis consumer technology and accessories space
• Flora Growth also announced a 2022 revenue guidance of $35-45 million
• CEO Luis Merchan held a webinar on December 14 in which he highlighted the company’s 2021 operational performance, commented on the revenue guidance, and fielded questions

Flora Growth (NASDAQ: FLGC), an internationally focused company committed to delivering the most compelling customer experiences in the world through its collection of plant-based wellness and lifestyle brands, is building an ecosystem of products that will support market-leading innovation within categories that matter most to consumers exploring plant-based consumer goods. In fulfilling this objective as well as its operational tenet ‘lead by design’, Flora Growth recently announced its wholly owned subsidiary, Vessel Brand, had introduced a robust portfolio of new products for… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office [email protected] CannabisNewsWire is part of the InvestorBrandNetwork.

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, recently published its third-quarter 2021 results. “SRAX reported third-quarter revenues of $8.3 million, a figure which was up 219% year-over-year and 8% on a quarter-on-quarter basis. The company also seized the opportunity to update their corporate revenue guidance, for $10.1 million Q4 revenues, whilst simultaneously re-affirming fiscal year 2021 guidance and raising their target to $31.5 million. SRAX’s stellar third quarter continues a trend that has seen the company’s financial returns go from strength to strength over the past year. The company comfortably met their revised Q3 revenue guidance of $8.3 million, which had been upgraded following the release of Q2 results,” reads a recent article. SRAX also reported third-quarter gross margins of 78%, up from 67% in the same period last year. “SRAX’s earnings announcement comes amidst a period of strong growth for the company. SRAX revealed that their Sequire investor intelligence platform had seen the number of subscribers swell to 250 public companies, a dramatic increase relative to the 225 companies on the platform in the second quarter and up from a mere 92 subscribers as of the Q3 2020 results.”

To view the full article, visit https://ibn.fm/237XZ

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art, signal-processing components for satellite and 5G communications networks, defense, space and other commercial applications, has completed the purchase of the assets and operations of Spectrum Semiconductor Materials Inc. Based in California, Spectrum is a rapidly growing global specialty distributor of semiconductor components. According to AMPG, the transaction should provide significant financial benefits to the company while also adding significant distribution reach. The announcement noted that Spectrum is on track to reach unaudited 2021 revenue $13 million unaudited revenue for 2021. The announcement also observed that Spectrum has an existing powerful distribution platform across the United States, Europe and Asia, which is ideal for AmpliTech’s new line of monolithic, microwave-integrated circuit (“MMIC”) chip designs. “Through the Spectrum acquisition we have substantially increased our revenue base with a well-managed, growing business known for high quality and excellent customer service,” said AmpliTech CEO Fawad Maqbool in the press release. “We expect the transaction will be immediately accretive to our top-and bottom-line financial performance. Spectrum also provides an ideal distribution platform to support the launch and commercialization of our MMIC chip solutions in core end markets of aerospace, defense, automotive and computing. We expect AmpliTech and Spectrum to play a key role in improving the speed and efficiency of 5G cellular networks and medium earth orbit and low earth orbit satellite communications systems around the world.” To view the full press release, visit https://ibn.fm/xi0tU About AmpliTech Group Inc. AmpliTech designs, develops and manufactures state-of-the-art radio frequency (“RF”) components for global satellite communications, telecom (5G and IoT), space, defense and quantum computing markets as well as systems and component-design consulting services. AmpliTech has a 13-plus-year track record of developing high-performance custom solutions to meet the unique needs of some of the largest companies in the global industries that it serves. The company is proud of the unique skills, experience and dedication of its focused team, which enables AMPG to deliver superior solutions, faster time to market, competitive pricing and excellent customer satisfaction and repeat business. For more information about the company, please visit www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”). The award is for CYBN’s patent application related to CYB004, an investigational deuterated psychedelic tryptamine compound developed for the potential treatment of anxiety disorders. According to the announcement, allowed claims under the award also include other forms of deuterated psychedelic tryptamine. This award expands Cybin’s intellectual property portfolio and strengthens the company’s position as leading innovator in developing putative psychedelic compounds. According to the company, CYB004 has the potential to effectively treat anxiety disorders without some of the common side effects associated with current treatments. “The receipt of this Notice of Allowance from the USPTO represents an important milestone in expanding our intellectual property portfolio progressing psychedelics to therapeutics for the countless patients in need, and strongly demonstrates the Company’s dedication to the discovery and development of differentiated psychedelic-based compounds for addressing mental health,” said Cybin CEO Doug Drysdale in the press release. “Once issued, this patent may have the opportunity to cover a broad range of claims supporting our IP in psychedelic medicine and further strengthen our emerging best-in-class position in this evolving industry.”

To view the full press release, visit https://ibn.fm/AsMaV

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Patent filings are held by Cybin IRL Limited, a wholly owned subsidiary of Cybin. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

• Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021
• The event came right after the company announced human clinical hypertension study HYPER-H21-4, its most ambitious one yet
• Lexaria plans to sublicense its patented DehydraTECH(TM) technology worldwide, allowing for more people to benefit from it
• Going into 2022, the company looks forward to reporting on results from its HYPER-H21-3 clinical study and receiving Independent Review Board (“IRB”) approval for its HYPER-H21-4 study

Lexaria Bioscience (NASDAQ: LEXX) just participated in this year’s Benzinga Global Small Cap Conference. The two-day event was a showcase for small cap investing, bringing together shareholders, entrepreneurs, and investors. George Jurcic, the head of Investor Relations (“IR”) at Lexaria, represented the company. He was among 50 other speakers who took the stage in this event that featured 15-minute company presentations… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office [email protected]

Energy Fuels (NYSE American: UUUU) (TSX: EFR) today announced the execution of a memorandum of understanding (“MOU”) with Nanoscale Powders LLC (“NSP”) for the development of an innovative technology for the production of rare earth element (“REE”) metals. “Metal-making is a critical step in the rare earth supply chain. Energy Fuels has already restored monazite ‘crack-and-leach’ capabilities to the U.S. at our White Mesa Mill in Utah, where today we are producing a high-purity mixed rare earth carbonate, which is ready for separation. No other company in the U.S. is currently producing a high-purity REE product ready for separation at commercial levels. We are also quickly moving toward adding solvent extraction separation equipment at the Mill and associated permitting that will allow us to produce commercial separated rare earth oxide powders in the coming years,” said Energy Fuels president and CEO Mark S. Chalmers. “The next step in rare earth processing and refining is turning those separated rare earth oxide powders into usable rare earth metals and alloys, particularly NdPr metal needed for NdFeB magnets used in EVs, wind generation and other technologies. We are interested in Nanoscale Powders’ technology because we believe it has the potential to produce REE metals at lower cost, using less energy, and producing significantly less greenhouse gas emissions than conventional REE metal making methods. If successful, Nanoscale’s metal-making technology could be orders of magnitude safer and less expensive than the current established technology. This is the type of technology we as Americans need to develop to produce advanced rare earth materials in a cost-competitive manner, while achieving the highest standards of protection of public health, safety and the environment. Nanoscale Powders has proven their technology on a small scale, and we look forward to working with them to advance the technology to pilot scale, and then to commercial scale in the coming years. Our relationship with Nanoscale Powders demonstrates Energy Fuels’ commitment to fully integrating a domestic REE processing supply chain in the most optimal and environmentally prudent manner possible.”

To view the full press release, visit https://ibn.fm/Vy3Ey

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and is ramping up to commercial-scale production of REE carbonate. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States . Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate and uranium from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol UUUU, and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol EFR. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
[email protected]

MiningNewsWire is part of the InvestorBrandNetwork.

Nemaura Medical (NASDAQ: NMRD) has developed a platform to monitor multiple chemicals in the blood without needles, replacing traditional invasive methods of diagnosis and health care observations. With the global continuous glucose monitoring (“CGM”) devices market expected to reach $19.04 billion in 2028 from $4.11 billion in 2020, according to an analysis by Reports and Data (https://ibn.fm/UBSIU), key companies in the space, including Nemaura Medical, are ideally positioned to benefit from this growth as they work to meet the needs of the industry. CGM devices enable tracking of blood glucose levels around the clock by monitoring the levels via sensors that send readings to the receiver’s device screen or smartphone. They aid patients in managing diabetes with lesser fingerstick tests. “Nemaura Medical’s proprietary sugarBEAT(R) device is the world’s first-of-its-kind non-invasive continuous glucose monitoring sensor designed for use by ‘everyone,’ meaning people dealing with either type 1 or type 2 diabetes as well as those with prediabetes,” reads a recent article. “The device attaches on (not under) the skin and measures real-time blood glucose levels every five minutes. This invaluable information allows individuals to make adjustments to their diet and activity that can significantly change their lives.”

To view the full article, visit https://ibn.fm/n4EXK

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a Premarket Approval Application (“PMA”) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a preclinical study focusing on CYB003, one of its psilocybin programs. A recent article quotes CEO Doug Drysdale as saying, “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental health care, but few companies have addressed the well-known limitations and side effects of oral psilocybin… Cybin has always strived to develop safer and more effective therapies for patients, which has guided our multiple psilocybin programs: CYB001, CYB001 and CYB003.” The positive CYB003 preclinical findings demonstrate distinctive advantages for its newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. The CYB003 program is designed to maintain the benefits of oral psilocybin, which, according to previous research, appears to be efficacious in treating mental health disorders while addressing associated challenges, including the slow onset of action, extended duration of effect and variability in response among patients.

To view the full article, visit https://ibn.fm/S9VEQ

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC), a company guided by the mission to build a connected, design-led collective of plant-based wellness and lifestyle brands that provide customers with a one-of-a-kind experience, recently announced it had closed the acquisition of Vessel Brand Inc., an industry leader in cannabis consumer technology. “This marks the addition of an exceptional brand builder with a proven track record of not only launching successful cannabis-related brands but also capturing market share in the rapidly-expanding United States cannabis landscape,” reads a recent article. “When making the announcement, Luis Merchan, the president and CEO of Flora Growth, noted, ‘With this acquisition now closed, we can focus on the execution of our combined expansion strategy… The integration of our two organizations is well underway, and the Vessel team is expected to substantially enhance the branding and marketing function of Flora Growth as we look to further increase market share in the global cannabis and wellness markets.’”

To view the full article, visit https://cnw.fm/As8W0

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

• SRAX’s BIGtoken platform announced their merger with BritePool Inc on September 27th, with both entities officially completing their merger on December 2, 2021
• SRAX have simultaneously revealed that they will no longer consolidate BIGtoken’s financials within their financial results
• Post-merger, SRAX’s core operations will focus on investor intelligence SaaS platform, Sequire, which now boasts over 9 million followers and 250 corporate subscribers
• Sequire has forecast to report $16.5 million in 4Q21, an accomplishment which would mark the company’s 12th consecutive quarter of revenue growth

SRAX (NASDAQ: SRAX) a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has recently announced that it will no longer have to consolidate the financials of its former subsidiary, BIGtoken, Inc (https://ibn.fm/ULbBn). BIGtoken, a proprietary consumer insights platform founded and operated by SRAX, Inc, was created with the purpose of enabling the over 16.7 million consumers on their platform to both own and monetize their digital data in an efficient and transparent manner. In turn, the platform’s customers – which… Read More>> NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products by Bidi(R) Vapor LLC, including the BIDI(R) Stick disposable electronic nicotine delivery system (“ENDS”), and Bidi Vapor announced that a recent survey showed  that 80% of adult e-cigarette users and cigarette smokers who responded prefer the BIDI Stick over their current options, including open systems, cartridges/pods and other disposable e-cigarettes. The survey was conducted in the United Kingdom by North Carolina-based research firm Voccii LLC and involved 101 adult users of vaping products and combustible cigarettes and tested preferences between four BIDI Stick flavors with the products that the subjects typically used. Additional survey results indicated that any flavors should do well in the UK (“UK”) market. “While the U.S. e-cigarette market numbers have shown that consumers prefer the BIDI Stick, we are ecstatic to see that the U.K. market research results confirms that the 2% nicotine BIDI Stick is similarly preferred by adult e-cigarette users and smokers in the U.K.,” said Bidi Vapor and Kaival Brands president and CEO Niraj “Raj” Patel in the press release. “From a market perspective, the U.K. has unique regulatory standards that help with direct comparisons between competing devices. For instance, all e-cigarettes must have no more than 2% nicotine levels and tank sizes cannot surpass 2 ml. It’s comforting to know you’re competing on a level playing field.”

To view the full press release, visit https://ibn.fm/k4De7

About Kaival Brands Innovations Group Inc.

Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor. For more information about the company, visit www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced a strategic partnership with ARRK, a leading automotive engineering company based in Munich, Germany. According to the update, ARRK will be supporting Mullen Automotive in Computer Aided Engineering (“CAE”), body in white, battery, closures, interior, chassis, thermal, and infotainment engineering. ARRK will initially support the Mullen FIVE EV Crossover and then move into future vehicles, including a seven-seat SUV program. “ARRK is a leading automotive engineering company with a global footprint, including working with some of the most well-respected automotive manufacturers, such as BMW, VW brands and Mercedes-Benz,” said David Michery, CEO and chairman of Mullen Automotive. “Their vehicle engineering expertise will be a key component for us in hitting our production timeline for the FIVE and beyond.”

To view the full news release, visit https://ibn.fm/jek70

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

• Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022
• The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications
• Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral nicotine delivery

Diabetes, rheumatoid disease, Alzheimer’s Disease, and estrogen delivery, are some of the multiple indications that drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) is planning to target with its research and development programs next year. The markets targeted provide multiple opportunities for success and are now expected to reach an overall estimated value of more than $160 billion annually, worldwide over the next few years. The company will conduct pharmacokinetic and efficacy modelling studies to determine if its patented DehydraTECH(TM) technology can be used successfully to improve delivery of drugs or active pharmaceutical… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge. Receive Text Alerts from CBDWire: Text “Cannabis” to 21000 For more information please visit https://www.cbdwire.com and or https://CBDWire.News Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer CBDWire (CBDW) Denver, Colorado cbdwire.com 303.498.7722 Office [email protected]

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that its next stop in showcasing the Mullen FIVE EV Crossover, including the debut of level 5 autonomous vehicle technology, will be at the Consumer Electronic Show (CES(R)) in Las Vegas from Jan. 4 – 8, 2022. Mullen will be featured in the Las Vegas Convention Center’s West Hall for the duration of the CES, showcasing the FIVE, including autonomous, powertrain and battery technology. “Our next stop is CES in Las Vegas this coming January. We had tremendous, overwhelmingly positive reaction to the FIVE at the L.A. Auto Show, with many people saying it was the best-looking vehicle at the show and winning the Top SUV EV category, beating out both Rivian and Lincoln,” said David Michery, CEO and chairman of Mullen Automotive. “CES is a one of the best, if not the best, consumer technology event in the world. We are looking forward to starting 2022 in Las Vegas at CES with the Mullen FIVE EV Crossover.”

To view the full news release, visit https://ibn.fm/LQUJY

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, has made available key presentations from its Sequire Clean Tech & Electric Vehicles Conference. The premier virtual investor event was held on Dec. 6, 2021, and featured presentations from more than 25 elite stock market companies that are leading the way in the clean-tech space; the event also included insightful addresses and discussions with industry execs looking at the future of clean tech. Topics covered electric vehicles, energy and power, and materials and chemicals. Replays of the keynote addresses and company presentations are available on the event website for three months. To view the presentations, visit https://ibn.fm/JbYnU To view the full press release, visit https://ibn.fm/IeI9l About SRAX Inc. SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, please visit www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following the acquisition of BayMedica Inc. in October that created an industry leader in the manufacture and commercialization of rare cannabinoids, management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products. In late September, InMed commenced the 755-201-EB study, its phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). A recent article reads, “The commencement of the study marked the first time cannabinol has advanced to a phase 2 clinical trial to be evaluated as a therapeutic option for disease treatment… InMed has also developed a cannabinol (‘CBN’) topical eye drop formulation currently the subject of preclinical studies as a potential treatment for glaucoma… InMed continues to work toward completing the INM-088-based preclinical studies in preparation for human clinical trials. The company anticipates filing regulatory applications in the second half of the 2022 financial year to commence human clinical testing with INM-088.”

To view the full article, visit https://ibn.fm/UY4q0

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed Pharmaceuticals is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Company receives grant to fund clinic for marginalized, underserved NYC communities
• New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service
• Program’s clinicians will receive specialized training

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA). Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East Side of Manhattan, New York. The hospital is… Read More>> NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.PsychedelicNewsWire.com Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW) San Francisco, California www.PsychedelicNewsWire.com 415.949.5050 Office [email protected] PsychedelicNewsWire is part of the InvestorBrandNetwork

• Colombian cannabis cultivator and international wellness product builder Flora Growth Corp. is building a global pipeline for its wide array of branded CBD and medicinal cannabis products
• The company recently announced that it has begun fulfilling the first orders for its Mind Naturals and Awe CBD skincare brands with exports to Spain and Mexico outlets this month
• Flora Growth cultivates cannabis at its 100-hectare (247-acre) property in central Colombia
• Flora also has a GMP certified 16,000-square-foot manufacturing facility in Bogota that produces nearly 200 products for the CBD derivatives and medical cannabis markets

Cannabis cultivator and worldwide cannabidiol (“CBD”) brand builder Flora Growth (NASDAQ: FLGC) continues to expand its consumer product goods and wellness lifestyle technology internationally, recently receiving its first orders for its Mind Naturals and Awe CBD skincare brands from outlets in Spain and Mexico. The company’s e-commerce agreements with SHOWFIELDS and GlossWire’s digital beauty marketplace in October paved the way for the two skincare brands to roll out in international markets. Fulfillment of these initial purchase orders from Amma Spain and Mexico’s… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office [email protected] CBDWire is part of the InvestorBrandNetwork.

BioRestorative Therapies (NASDAQ: BRTX), a life sciences company focused on adult stem cell-based therapies, announced the pricing of the underwritten public offering of 2,300,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock at a per unit price of $10.00. According to the update, the warrants have a per share exercise price of $10.00, are exercisable immediately and expire five years from the date of issuance. As a result of the offering, the company’s common stock began trading under the ticker symbol BRTX on the Nasdaq Capital Market on Nov. 5, 2021. The offering closed on Nov. 9, 2021. In addition, BioRestorative Therapies granted to the underwriters a 45-day option to purchase up to 345,000 additional shares and/or warrants to purchase up to 345,000 shares of common stock to cover over-allotments, if any. Roth Capital Partners acted as sole manager for the offering.

To view the full press release, visit https://ibn.fm/5d3BT

About BioRestorative Therapies Inc.

BioRestorative Therapies develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The company’s two core programs, brtxDISC(TM) and ThermoStem(R), relate to the treatment of disc/spine disease and metabolic disorders. For more information about the company, visit www.BioRestorative.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

• Around 40% of available marketed drugs are poorly bioavailable or soluble, and about 90% of New Chemical Entities are known for their low solubility and permeability
• Lexaria’s patented DehydraTECH(TM) technology offers a solution by improving how APIs (active pharmaceutical ingredients) enter the bloodstream
• DehydraTECH achieves this by bypassing first-pass-liver metabolism
• By doing so, Lexaria is facilitating faster and much more thorough drug delivery

In a report published in the Bioavailability Enhancement Technologies and Services Market, 2018-2030, it was established that around 40% of available marketed drugs are poorly bioavailable or soluble. It was further estimated that approximately 90% of New Chemical Entities (“NCEs”) belong to Biopharmaceutics Classification System (“BCS”) class II and IV, known for their low solubility and permeability (https://cnw.fm/3KzzB). Today, a significant number of drugs fail to reach the market owing to their poor bioavailability. This has prompted companies to re-formulate existing product candidates and explore different tools and… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office [email protected] CannabisNewsWire is part of the InvestorBrandNetwork.

• Charles Schwab survey shows 15% of retail investors started during the COVID-19 pandemic in 2020
• SRAX’s Sequire premier IR communications platform assists public companies understand and communicate with the investment community
• After following SRAX to understand its expertise, Sino American Oil Company has engaged SRAX
• More than 250 companies now use Sequire, driving revenue to $8.3 million in Q3 and on the way to the high-end of 2021 guidance

The coronavirus pandemic changed many things in the world, and you can be sure investing is on the list. According to a Charles Schwab survey earlier this year, about 15 percent of today’s retail investor population got started in 2020, a group Schwab has labeled “Generation Investor.” In the survey of about 1,000 people, Schwab also learned that investing respondents are taking a long approach and that it isn’t just younger generations putting their money in the market, a mix that bodes well for communications specialists like SRAX (NASDAQ: SRAX). SRAX is a diversified financial technology, digital marketing and consumer data management company that provides an array of consumer data to its clients valuable to marketing and communications. SRAX’s flagship offering is a premier investor intelligence and… Read More>> NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, through its wholly owned subsidiary Vessel Brand, has entered the dry herb market. Vessel Brand is expanding into the market with a line of exclusive products, including an all-in-one dry herb smoking kit with an inverted lighter, a premium grinder, an artful ashtray and the company’s own take on the one-hitter with a spiralized interior. A flagship product in the new line of offerings is the Helix, a patent-pending, pure brass device designed to offer the cleanest inhalation possible. Another item grabbing attention is Vessel’s new customizable, “just-add-flower” Eclipse set, which includes the choice of a one-hitter (either the Helix or Vessel’s tapered glass chillum, called Air) as well as a waterproof Basin stash jar and a carbon lighter. New products still slated for release include a functional concrete-and-walnut ashtray made with concrete and real walnut and the new Grinder, a four-piece construction made with precision-engineered aluminum and magnetic closures for easy use. Flora Growth also announced its upcoming earnings webinar, scheduled for Dec. 14, 2021. Flora CEO Luis Merchan will provide an overview of the company’s operational performance during the call, as well as answer questions. “At Vessel, we work tirelessly to set new industry standards and look forward to continuing to deliver on that brand promise within the dry herb market,” said Vessell founder and CEO James Choe in the press release regarding the company’s expansion into the dry herb market. “These new products are just the beginning of what Vessel has in store for consumers across the globe.”

To view the full webinar, visit https://cnw.fm/Tncs9

To view the full press release, visit https://cnw.fm/LIAuO

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

• 1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease
• As many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passing
• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• In addition to sugarBEAT, its flagship device, the company also recently announced the launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores

By 2024, the International Diabetes Federation (“IDF”) predicts that the number of people with diabetes is expected to rise to 1 in 8 adults. Nearly 7 million adults have died worldwide in 2021 so far due to diabetes or its related complications – astoundingly, accounting for over 1 in 10 global deaths from any cause. While enormous, that figure does not consider the lives lost to the novel coronavirus, which has shown to be particularly deadly for people with diabetes. A study found that having Type 1 or Type 2 diabetes tripled the risk of severe illness or death from COVID-19 (https://ibn.fm/laj37). “As many as 40% of the people that have died in the US from COVID-19 had diabetes,” said Dr. Robert Gabbay, chief scientific and medical officer for the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Save Foods (NASDAQ: SVFD), an agri-food-tech company focused on developing and selling eco-friendly products specifically designed to extend the shelf life and ensure food safety of fresh fruits and vegetables, has completed the first commercial sale of its treatment for Medjool dates in the Arava region in Israel, which is the largest exporter of Medjool dates in the world. The sale was completed with Galilee Export, the second largest exporter of fresh produce in the country. This sale comes on the heels of an earlier announcement regarding the company’s first sales in the same region of its treatment for bell peppers. According to the announcement, Galilee Exports will begin broad-scale commercial treatment of its Medjool dates during the upcoming season. Growing and harvesting Medjool dates is more labor intensive than other produce because cannot be picked until they ripen on the trees; other dates ripen after harvesting. Therefore, the cost of harvesting Medjool dates is higher, and Save Foods treatments allow Galilee Exports to maximize the revenues of each harvest, while providing consumers with the highest-quality product, said a Galilee Exports representative. “The benefits of Save Foods’ treatment are recognized on a continuously growing number of produce, Medjool dates being one of them,” said Save Foods CEO Dan Sztybel in the press release. “Our relationship with Galilee Export represents a significant opportunity for the company beyond dates; they have a well-established and growing presence in the global produce market, and a reputation for high-quality produce. I am confident that we will continue to expand our partnership to include new crops and exposure to new markets going forward.” To view the full press release, visit https://ibn.fm/Zix3U About Save Foods Inc. Save Foods is an innovative, dynamic company addressing two of the most significant challenges in the agri-food-tech industry: food waste and loss, and food safety. The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops innovative solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and consumers alike. SVFD’s initial applications are in post-harvest treatments in fruit and vegetable packing houses processing citrus, avocado, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of hazardous chemicals and their residues, Save Foods products not only prolong fresh produce shelf life and reduce food loss and waste, but they also ensure a safe, natural and healthy product. For more information about the company, visit www.SaveFoods.co. NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at https://ibn.fm/SVFD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve delivery of lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (“APIs”) into the bloodstream while speeding onset, increasing bioavailability and improving efficacy. DehydraTECH’s ability to enhance delivery promotes healthier oral ingestion methods and increased effectiveness of fat-soluble active molecules.  As demonstrated through in vivo, in vitro and human clinical testing, DehydraTECH enables fast-acting, less expensive and more effective oral drug delivery. The company operates an in-house research laboratory and has continued to strengthen and broaden its DehydraTECH technology, initially developed in 2014. Lexaria holds an intellectual property portfolio consisting of 23 patents granted in over 40 countries with a combined population of 2.6 billion, as well as over 50 additional patents pending worldwide. Lexaria licenses DehydraTECH to companies around the globe to offer consumers the best possible performance across an array of ingestible products. DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions. The company’s technology offers a delivery method that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effective ness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including for use in industries that produce cannabinoid beverages, edibles and oral products, as well as for a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products. For more information, visit the company’s website at www.LexariaBioscience.com. To learn more about Benzinga’s Small Cap Conference, visit: https://ibn.fm/BenzingaSmallCapDec2021 About InvestorBrandNetwork’s Virtual Coverage The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, provides the online investment community with custom-built portals that include summaries on hundreds of presenting companies. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of various investor conferences. For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer InvestorBrandNetwork (IBN) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office [email protected]

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, has seen a significant rise in its financial returns over the past year. “For the second quarter of fiscal 2021, the company reported Q2 revenues of $7.7 million, up 557% year-over-year, and rising by 41% quarter-on-quarter. The company also seized on the opportunity to update their corporate revenue guidance, increasing Q3 guidance to $8.3 million, which would represent at least a +7.7% quarter-on-quarter increase. SRAX also increased their full year revenue target to $32 million, up from $30 million previously,” reads a recent article. “Immediately following the second quarter earnings report, SRAX announced that they would be carrying out a simultaneous $10 million stock buy-back program as well as paying a one-time special dividend to its shareholders of record as of the 20th of September 2021. The special dividend, which would bear an approximate value of $0.23 per common share, would be in the form of an issuance of non-tradeable preferred shares, which would hold a notional value of approximately $6.5 million worth of Sequire’s clients’ stock. As the underlying shares are sold, the proceeds will be distributed to the preferred shareholders on a periodic basis.”

To view the full article, visit https://ibn.fm/hNOu0

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

• SRAX reported their 3Q21 quarterly results on November 15, 2021
• The company reported 3Q21 revenues of $8.3 million, +219% YoY and +8% QoQ
• SRAX also reported that their 3Q21 EBITDA net loss narrowed to -$790k, with the company simultaneously revealing that their gross margin had widened to 78%
• SRAX’s investor intelligence platform, Sequire announced that their subscribers had swelled to 250 companies as of 3Q21, up from 225 companies at the end of the second quarter

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, recently published its third quarter 2021 quarterly results on Monday, November 15th (https://ibn.fm/vC1PH). SRAX reported third quarter revenues of $8.3 million, a figure which was up 219% year-over-year and 8% on a quarter-on-quarter basis. The company also seized on the opportunity to update their corporate revenue guidance, guiding for $10.1 million in Q4 revenues, whilst simultaneously re-affirming their fiscal year 2021 guidance and raising their target to $31.5 million. SRAX’s stellar third quarter continue a trend which has seen the company’s financial returns go from strength to strength over the past year. The company comfortably met their revised Q3 revenue guidance of $8.3 million, which had been upgraded following the release of Q2 results, whilst concurrently announcing Sequire’s 3Q21 bookings of… Read More>> NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

NetworkNewsWire Editorial Coverage: Keeping up with precise documentation and a myriad of regulations is not only burdensome for physicians, it also restricts important physician/patient interaction and limits accurate and compassionate patient care. Many in healthcare believe it is the single largest pain point in the physician/patient relationship. The idea of outsourcing this task to third parties that have the resources and expertise to generate the requisite documentation much more cost effectively seems like a rational economic division of labor.  And make no mistake about it, technology is increasingly tipping the scale in favor of virtual documentation solutions with the latest advances in automatic speech recognition (“ASR”) and natural language processing (“NLP”).  These technologies are integral to the virtual documentation solutions developed by Augmedix Inc. (NASDAQ: AUGX) (Profile). A pioneer in virtual, real-time, medical-note documentation, Augmedix is “re-humanizing healthcare” and alleviating healthcare system pressures with its unique digital health platform that provides virtual medical documentation and live clinical support. The company is at the vanguard of the next generation of technologies being integrated into a healthcare marketplace that is notoriously cautious to make changes. Along with Augmedix, others in the sector, such as Vocera Communications Inc. (NYSE: VCRA), Phreesia Inc. (NYSE: PHR), American Well Corporation (NYSE: AMWL), and DarioHealth Corp. (NASDAQ: DRIO), are leading a transformational shift in healthcare to a more efficient…

Read More >>

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Fashion can be fun but make no mistake, it can be profitable too. The global apparel market is coming off a historic decline caused by lockdowns, social distancing, and economic slowdowns due to the COVID-19 outbreak and the measures to contain it. COVID still lingers but the apparel market looks ripe for rebound and ready to hit new highs. During the lockdown, consumers strayed away from purchasing new apparel. However, apparel companies still have the potential to deliver good earnings and significant capital gains. Not only is the industry huge, but it also ripe for rebound with much higher seasonal demand during the holidays. Time to shed the sweatpants, get dressed for success and get serious about some apparel.

Some the largest, most popular apparel labels are owned and operated by unfamiliar names like PVH Corp. (NYSE: PVH) which has multiple brands under its umbrella including Van Heusen, Tommy Hilfiger, and Calvin Klein among others. Formerly known as the Phillips-Van Heusen Corporation, PVH also licenses brands such as Kenneth Cole New York and Michael Kors. PVH is one of the largest global apparel companies in the world reporting $7.1 billion in 2020 revenues. PVH reported third-quarter fiscal 2021 results, where the bottom line surpassed the Zacks Consensus Estimate, while the top line missed the same. However, both metrics improved year over year. The Calvin Klein segment improved 22% year over year and the Tommy Hilfiger segment rose 12%. A top hedge fund, Pzena Investment Management, had $439 million invested in…

Read More >>

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has started the initial validation testing of its exclusive Class 2 EV cargo van. The testing is taking place at Mullen’s Advanced Manufacturing and Engineering Center (“AMEC”), which is located in Tunica, Mississippi. Based on a 144-inch wheelbase, Mullen’s Class 2 EV cargo van features a 78.8-kWh battery pack as well as rear-wheel drive and a  modular 460-cubic-foot cargo area. In addition, the vehicle offers a range of more than 200 miles and a maximum payload of 3,296 pounds. “Our Class 2 EV cargo van initial validation testing has begun at our AMEC facility in Tunica,” said Mullen Automotive CEO and chair David Michery in the press release. “The Mullen One is our first major manufacturing program out of our Tunica facility, and the entire team in California and Mississippi is excited to be working on the EV Cargo Van program.”

To view the full press release, visit https://ibn.fm/AuMN1

About Mullen

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

With the nascent electric vehicle sector poised to grow exponentially over the next decade, a couple of firms companies that haven’t been in the automotive sector have thrown their hats into the electric vehicle ring. Amazon, for instance, has invested billions of dollars in Rivian, an EV startup that will build electric vans, pickup trucks and SUVs. A new report from Bloomberg indicates that Apple (NASDAQ: AAPL) is working on an autonomous electric vehicle that will launch in 2025.

Although Apple hasn’t confirmed whether or not it will launch a self-driving EV by 2025, the Bloomberg report says that the technology company is fast-tracking its plans to enter the vehicle market.  According to Bloomberg, Apple’s vehicle engineers have explored two types…

Read More >>

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products, recently announced 2022 revenue guidance of $35-45 million. According to the update, this incorporates revenue contributions from the company’s various operating divisions, including recently acquired Vessel Brand and wholesale cannabis revenues from Cosechemos. In addition, Flora announced that it will hold a webinar at 4:30 p.m. ET on Tuesday, Dec. 14, 2021. During the webinar, Flora CEO Luis Merchan will provide an update on the operational performance for 2021 to date, additional comments on the financial guidance for 2022, and hold a brief question-and-answer session. Interested parties should visit https://ibn.fm/rAHCl to register and submit questions in advance of the webinar. To view the full press release, visit https://ibn.fm/uiKJN About Flora Growth Corp. Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received approval from the Switzerland Ethics Committee (swissethics) — the first approval of its kind from a European ethics committee — for its study of Berubicin. Exclusive to CNS Pharmaceuticals, Berubicin is the first anthracycline that appears to cross the blood-brain barrier; the substance is being assessed in a global study designed to evaluate efficacy and safety in the treatment of recurrent glioblastoma multiforme (“GBM”). The adaptive, multicenter, open-label, randomized and controlled study is set to begin soon and will have study sites across Europe and in the United States. “Receiving approval from swissethics is a significant milestone for the company,” said CNS Pharmaceuticals CEO John Climaco in the press release. “Our stated goal is, and always has been, to see Berubicin approved for the treatment of glioblastoma, and this means globally. This terrible disease does not discriminate on the basis of geography or anything else: patients in Europe are as desperate as patients in the United States , and treating patients is not only why we do what we do, but how we do it as well. Driving patient enrollment is how we advance Berubicin’s development and opening additional clinical sites around the globe is the pivotal piece that allows us to ramp up our efforts and move toward data. We are deeply grateful that Switzerland has the first European EC to approve our Berubicin trial, but we are confident it will be far from the last in this truly global effort. We have a number of additional clinical sites selected around the world that we anticipate coming online in the very near term. As we progress, my belief grows in the enormous potential of Berubicin to be a critical treatment option for this devastating  disease. I am proud of the accomplishments we’ve made with this potentially pivotal trial to-date, but we will not pause for a single second until Berubicin reaches its full potential to offer hope to GBM patients everywhere.”

To view the full press release, visit https://ibn.fm/1Hsp7

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. Additionally, CNS Pharmaceuticals is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small-molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain, pancreatic and ovarian cancers as well as lymphomas. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, blood pressure findings from HYPER-H21-3 will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4. The study protocols for HYPER-H21-4 are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. HYPER-H21-4, which will be more comprehensive than Lexaria’s previous studies, is expected to involve 60 different volunteers aged between 45 and 70 years. Each of them will use three 150 mg doses of DehydraTECH-CBD every day over six weeks. A recent article notes, “The eventual goal is to seek regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure, and data from this study could be instrumental to that pursuit.”

To view the full article, visit https://cnw.fm/3cpKW

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Excellon Resources (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) is a diversified metals producer with a precious metals growth pipeline that includes Mexico’s Platosa Mine, Kilgore, a high-quality gold development project in Idaho, as well as and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany boasting more than 750 years of mining history. The company recently released details of its robust second-quarter production numbers generated from its Durango, Mexico-based Platosa Mine. “Excellon saw silver production of 296,013 ounces, lead production of 1.9 million pounds and zinc production of 2.5 million pounds — in aggregate totaling silver equivalent production of 487,009 ounces,” reads a recent article. “Although comparable results relative to the equivalent period in 2020 were impacted by the suspension of activities in Mexico, from April 2 to June 1, 2020, on account of the COVID-19 outbreak, the second quarter of 2021 marked the fourth consecutive quarter during which Excellon’s Platosa mine witnessed over 21,000 tons mined and milled.”

To view the full article, visit https://ibn.fm/bqAjX

About Excellon Resources Inc.

Excellon’s vision is to create wealth by realizing strategic opportunities through discipline and innovation for the benefit of its employees, communities and shareholders. The company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality advanced exploration gold project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration. The company also aims to continue capitalizing on current market conditions by acquiring undervalued projects. Additional details on Excellon’s properties are available at www.ExcellonResources.com.

NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
[email protected]

MiningNewsWire is part of the InvestorBrandNetwork.

• Flora Growth recently entered into a licensing agreement to produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia, with an initial focus on the U.S. market
• The company will produce the product line using molecular tagging and authentication technology that will guarantee product verification and allay concerns of counterfeit products
• Through the licensing agreement, Flora has entered into the cannabis beverages market amid increasing demand for CBD-based products
• The recent agreement follows a November 15 announcement that FLGC had completed the acquisition of Vessel Brand Inc., an industry leader in luxury cannabis consumer technology

Internationally focused cannabis brand builder Flora Growth (NASDAQ: FLGC) recently signed a licensing agreement with Tonino Lamborghini, a luxury brand operating in the high-end designer products, hotel, beverage, and real estate segments. Under the terms of the partnership announced November 29, Flora Growth will produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia (https://cnw.fm/TEm9L). The Tonino Lamborghini product line, which will be produced in Florida for initial sale in US states where cannabidiol (“CBD”) ingestible are legal, will contain CBD and other premium cannabinoids, including cannabigerol (“CBG”). In addition, Flora will produce the product line using… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office [email protected] CBDWire is part of the InvestorBrandNetwork.

Over the next decade, automakers and electric vehicle (“EV”) startups alike will unveil dozens of new electric vehicle models. As the government looks toward achieving a carbon-neutral future, EVs have emerged as one of the best ways to reduce fossil fuel use and cut down greenhouse gas emissions.

Companies in the automotive sector have already invested billions of dollars in developing new electric vehicles for the EV market, which still makes up just a fraction of total vehicle sales. Fisker (NYSE: FSR), a California-based EV startup with backing from global alternative…

Read More >>

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

• Report notes significant and swift advancements in company R&D pipeline and overall business
• Preliminary data indicates CYB003 may provide significant treatment benefits that address limitations of oral psilocybin
• CYBN programs and new psychedelic chemical entities have potential to transform treatment landscape for various psychiatric and neurological conditions

Q2 2021 has been a transformative quarter for Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM). The company released its financial and operational report for the period recently, with notable company milestones and achievements highlighted (https://ibn.fm/ucAed). “The first half of the year has been a transformative period for Cybin that included significant and swift advancements in our research and development pipeline and overall business,” said Cybin CEO Doug Drysdale. “Through CYB003, we believe that we have identified a potentially safer treatment option for… Read More>> NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.PsychedelicNewsWire.com Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW) San Francisco, California www.PsychedelicNewsWire.com 415.949.5050 Office [email protected] PsychedelicNewsWire is part of the InvestorBrandNetwork

• NMRD releases fiscal Q2-2021 results, provides business update
• Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board
• Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently released its fiscal Q2-2021 results and provided a business update (https://ibn.fm/TX286). Financial highlights from the announcement included $26.8M cash on hand, and receipt of an initial $513,000 as deposit payment from its UK licensee as partial payment for an order of 200,000 sensors and… Read More>> NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is expanding internationally. The company’s Flora Beauty division received its first-ever orders for its Mind Naturals and Awe CBD skincare brands for the Spanish and Mexican markets; the company plans to ship the product this month. Flora Beauty’s Mind Naturals brand is designed with young consumers who are just starting a skincare routine while its the AWE brand targets consumers who value customized and personal experiences. The Mind Naturals line was recently named a top-12 finalist in a global pitch competition sponsored by Glosswire. The company also announced that legal and strategy vice president Damian Lopez has resigned to focus on other entrepreneurial ventures and board and advisory roles. “We are excited to expand our global reach over the coming months through Flora Beauty’s brands,” said Flora Growth CEO Luis Merchan in the press release. “The next few years will be pivotal for the evolution and expansion of the international cannabis market, and with our rapidly expanding portfolio of brands we intend to be at the forefront of this evolution.” To view the full press releases, visit https://cnw.fm/lgtcU About Flora Growth Corp. Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. For more information about the company, please visit www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office [email protected] CannabisNewsWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio) that may inhibit or slow the progression of neurogenerative diseases – such as Alzheimer’s, Parkinson’s, Huntington’s and others – by providing protection in a population of affected neurons. Furthermore, the application demonstrates the cannabinoid can also be used to promote neurite outgrowth, signifying the potential to enhance neuronal function. According to InMed’s Senior VP Pre-Clinical Research & Development Dr. Eric Hsu, who is quoted in a recent article, “This PCT patent application advances our strategy directed towards researching and developing rare cannabinoids as potential pharmaceutical therapeutics for diseases with high unmet medical needs.” Neurogenerative diseases affect millions of patients globally and are expected to affect millions more in the future; they are also projected to increase the individual, social and financial burden of taking care of patients. These factors demonstrate that finding treatments and cures is a matter of growing urgency, and “InMed’s patent application is, therefore, a promising start.” To view the full article, visit https://cnw.fm/eEMSv About InMed Pharmaceuticals Inc. InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed Pharmaceuticals is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office [email protected] CannabisNewsWire is part of the InvestorBrandNetwork.

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Faz Chowdhury, Ph.D., will present at the Benzinga Global Small Cap Conference. The event is scheduled to be held virtually from Dec. 8-9, 2021. Dr. Chowdhury will deliver his corporate presentation at 3:00 p.m. ET on Dec. 8 and will be available for one-on-one meetings throughout the conference. Interested parties should visit https://ibn.fm/puHmj to register for the event.

To view the full press release, visit https://ibn.fm/P72Au

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received authorization from the U.S. Food and Drug Administration (“FDA”) for an investigator-initiated, randomized, placebo-controlled phase 2 clinical trial; the trial is designed to evaluate psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The company noted that the primary investigator for the trial, Dr. Anthony Back, received an investigational new drug (“IND”) approval letter from the FDA, authorizing the trial. In addition, the study has received Institutional Review Board (“IRB”) approval at the University of Washington. Cybin also announced that CEO Doug Drysdale will be an active participant in the upcoming second annual H.C. Wainwright Psychedelics Conference. The virtual event is scheduled for Dec. 6, 2021. Drysdale will be part of a fireside chat, slated to start at 7 a.m. ET. Drysdale’s presentation will be available on demand; an archived version of the event will be available on the company’s investor relations website. “This clinical trial provides an opportunity to better understand the effectiveness of combining psilocybin and EMBARK,” said Cybin CEO Doug Drysdale in the press release announcing the phase 2 trial approvals. “Learnings from this combination Phase 2 trial will inform the use of EMBARK in Cybin’s upcoming human studies using CYB003, a proprietary deuterated psilocybin analog that has the potential to reduce clinic times and dosing levels in half as well as potentially reduce side effects and adverse events.”

To view the fireside chat, visit https://ibn.fm/s9Wqu

To view the full press releases, visit https://ibn.fm/Kjocw and https://ibn.fm/0MUmd

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

• Flora Growth has followed through with its definitive agreement to acquire 100% of Vessel’s equity interests
• This acquisition opens Flora up to the North American market, in addition to expanding its brand portfolio, with a proven operator that has achieved trailing 12-months revenue of $6.6 million and year-over-year growth of 90%
• It also serves to strengthen Flora’s management with the addition of Vessel’s leadership onto the team
• This latest acquisition lines up with Flora’s mission to build a connected, design-led collective of plant-based wellness and lifestyle brands that offer customers an unrivaled experience

Flora Growth (NASDAQ: FLGC) has, since its inception, made it its mission to build a connected, design-led collective of plant-based wellness and lifestyle brands that provide customers with a one-of-a-kind experience (https://cnw.fm/ZLUxY). In a move to live up to its mission, earlier in November 2021, the company entered into a definitive agreement to acquire Vessel Brand Inc., an industry leader in cannabis consumer technology (https://cnw.fm/e0gvp). On November 15, 2021, Flora announced having closed the acquisition of Vessel. This marks the addition of an exceptional brand builder with a proven track record of not only launching successful… Read More>> NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office [email protected] CannabisNewsWire is part of the InvestorBrandNetwork.

Lottery.com (NASDAQ: LTRY, LTRYW), a leading technology company that is transforming how, where and when the lottery is played, has appointed marketing veteran Greg Potts as its new global vice president of affiliate success. With more than two decades of strategic marketing experience, Potts has developed growth strategies for numerous consumer brands through targeted marketing efforts using co-op funding mechanisms. In his new position with Lottery.com, he will oversee the company’s business-to-business (“B2B”) growth strategy as well as its new Global Affiliate Marketing Program, which aims to add master affiliates and sub-affiliates while providing them with tools to accelerate the sales of Lottery.com products. Potts comes from Vericast, where he was a senior sales executive specializing in co-op marketing, customer activation and integrated media campaigns. In the coming weeks, Lottery.com is planning to unveil targeted multi-media marketing campaigns, including social media advertising, search engine optimization and interactive display advertising. In the announcement, Potts noted that Lottery.com’s new Global Affiliate Marketing Program offers an opportunity for the company to significantly grow its B2B2C user base. “On behalf of the entire team, we’d like to welcome Greg,” said Lottery.com CEO and co-founder Tony DiMatteo in the press release. “We expect that his experience and track record of successfully implementing affiliate market programs will be significant assets as we execute our strategic plan to expand and grow our B2B2C segment. Combined with our targeted marketing campaigns in our B2C segment, we anticipate reaching a wider audience and accelerating growth in both segments in 2022 and beyond.” To view the full press release, visit https://ibn.fm/bUykh About Lottery.com Lottery.com is a leading technology company that is transforming how, where and when lottery is played. Its engaging mobile and online platforms enable players and commercial partners located in the United States and around the world to remotely purchase legally sanctioned lottery games. Fans and subscribers look to Lottery.com for compelling, real-time results on more than 800 lottery games from more than 40 countries. Additionally, through WinTogether.org, Lottery.com is fundamentally changing how nonprofit donors are incentivized to action by gamifying charitable giving. In all that it does, Lottery.com’s mission remains the same: an uncompromising passion to innovate, grow a new demographic of enthusiasts, deliver responsible and trusted solutions, and promote community and philanthropic initiatives. To learn more about the company, visit www.Lottery.com. NOTE TO INVESTORS: The latest news and updates relating to LTRY are available in the company’s newsroom at https://ibn.fm/LTRY

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

Save Foods (NASDAQ: SVFD), an agri-food-tech company focused on developing and selling eco-friendly products specifically designed to extend the shelf life and ensure food safety of fresh fruits and vegetables, announced that it has received its first commercial sale of its PeroSTAR(TM) product. Two Israel-based, bell-pepper packing houses have ordered the product, which is formulated to ensure the safety and maximum shelf life of produce before it is exported. The packing houses tried the PeroSTAR treatment initially and, following positive results, decided to fully integrate the product into their treatment process. The packing houses are located in the Arava region, which produces approximately 60% of the fresh vegetables exported by Israel. Bell pepper, which are sold primarily to Russia, North America and the United Kingdom, are the leading export. This first commercial sale comes as the company also received regulatory approval of its product from the California Department of Pesticide Regulation (“CDPR”). “We are excited to see the first large-scale commercial implementation of our product for the bell pepper market, especially here in the heart of Israel’s thriving agriculture industry,” said Save Foods CEO Dan Sztybel in the press release. “We believe that the use of Save Foods’ treatment will help the Arava packing houses export produce of the highest quality without fungicides or a trace of hazardous residue.” To view the full press release, visit https://ibn.fm/IWdZY About Save Foods Inc. Save Foods is an innovative, dynamic company addressing two of the most significant challenges in the agri-food-tech industry: food waste and loss, and food safety. The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops innovative solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and consumers alike. SVFD’s initial applications are in post-harvest treatments in fruit and vegetable packing houses processing citrus, avocado, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of hazardous chemicals and their residues, Save Foods products not only prolong fresh produce shelf life and reduce food loss and waste, but they also ensure a safe, natural and healthy product. For more information about the company, visit www.SaveFoods.co. NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at https://ibn.fm/SVFD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.

• Growth in the uranium mining market is attributable to increase in nuclear fuel spend, reports the Business Research Company
• Report also noted key factors in projected growth of space, which should reach $10.18 billion by 2020
• UUUU is the leading U.S. producer of uranium, the fuel for carbon- and emission-free nuclear energy, in the country

The uranium mining market is projected to reach nearly $10.18 billion next year, according to a Business Research Company report, which noted that the industry should see CAGR of 4.6% during the forecast period (https://ibn.fm/vvT93). Energy Fuels (NYSE American: UUUU) (TSX: EFR), the largest producer of uranium in the United States, is committed to playing a significant role in the growing market. “The growth in the uranium ore mining market is due to increase in nuclear fuel spend in countries such as Australia, Kazakhstan and Canada owing to increasing spend in the defense industry,” stated the report, which noted that the uranium mining market consists of… Read More>> NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU About MiningNewsWire  MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge. To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only) For more information, please visit https://www.MiningNewsWire.com Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer MiningNewsWire Los Angeles, California www.MiningNewsWire.com 310.299.1717 Office [email protected] MiningNewsWire is part of the InvestorBrandNetwork.

At the recent 2021 OPSTech forum produced by The Monitoring Association (TMA), Microsoft (NASDAQ: MSFT) drilled home the premise that technology stakeholders need to embrace and understand the potential of AI.  The company’s Azure platform is a framework for developing AI solutions for enterprises.  Enterprises want to modernize their business processes quickly, and the Azure Artificial Intelligence Platform enables users to deliver breakthrough experiences via the use of industry-leading Vision AI models.

“Today’s leading-edge technologies, such as AI, give security integrators and monitoring services companies the ability to deliver new, higher levels of comfort, convenience, and security,” stated TMA President Morgan Hertel. “For our industry to compete successfully, service providers need to gain a strong understanding of AI and other technologies that are quickly emerging and gaining consumer interest.”

See the Latest Developments within the AI Space and Other Emerging Market Sectors

To view the live presentations to be delivered at the upcoming virtual Sidoti Conference, register at https://www.sidoti.com/events

 About Sidoti

For over two decades, Sidoti has been a premier provider of independent securities research. Our approach affords companies and institutional clients a combination of high-quality research and broad access to corporate management teams. We serve 500+ institutional clients in North America. Sidoti promotes meaningful interaction between issuers and investors through conferences and the hundreds of non-deal roadshows we host each year. For more information on Sidoti, visit https://www.sidoti.com

 About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently conducted a study on canines in collaboration with an independent testing laboratory. The analysis evaluated nicotine benzoate and polacrilex plasma levels in 40 anesthetized male beagle dogs comparing Lexaria’s recently developed, advanced DehydraTECH 2.0 nicotine formulation to concentration-matched controls. The dogs’ blood samples were taken every few minutes over the course of two hours. “The results from the study showed that the generic nicotine benzoate pouch required about 45 minutes to reach its peak delivery rate. In comparison, the DehydraTECH-nicotine benzoate pouch reached peak delivery rates at both eight minutes and again at 30 minutes. It was further noted that in just four minutes after the pouch was placed in the mouth, the DehydraTECH-nicotine had reached a higher delivery level than the generic achieved at any point during the study,” reads a recent article. Lexaria CEO Chris Bunka commented: “Our technology was ten to twenty times faster in delivering comparable levels of nicotine into bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction.” To view the full article, visit https://cnw.fm/zyFFL About Lexaria Bioscience Corp. Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office [email protected] CannabisNewsWire is part of the InvestorBrandNetwork.

• InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trials
• The company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 million
• Following the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare cannabinoids, growing revenue, and expanding sales
• InMed has commenced Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders
• Preclinical data of INM-088, the company’s cannabinol (“CBN”) formulation for the treatment of glaucoma, show CBN’s effectiveness in reducing cell death in retinal ganglion cells

For the three months ending September 30, 2021 (“Q1 2022”), InMed Pharmaceuticals (NASDAQ: INM), a global leader in pharmaceutical development, manufacturing, and commercialization of rare cannabinoids, witnessed positive momentum across all of its programs. And in a business update accompanying the release of its Q1 2022 financial results, the company discussed this momentum in relation to the progress made thus far (https://cnw.fm/dLKoa). On October 13, InMed closed the previously announced (https://cnw.fm/1zsA6) acquisition of BayMedica Inc., in a transaction that created an industry leader in the manufacture and commercialization of… Read More>> NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office [email protected] CannabisNewsWire is part of the InvestorBrandNetwork.

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reported its unaudited financial results and business highlights for the nine months ended Sept. 30, 2021. Financial highlights include total revenue reaching an estimated  $2.1 million, which is a 55.3% over the same period in 2020, and gross profit margin totaling 59.3%, representing an 8.8% increase from the year before. In addition, the average selling price of ANPC’s CDA-based tests was $71.6,  an increase of 72.3% from 2020. In addition, the company reported cash and cash equivalents of approximately $0.8 million for the nine-month period. Business highlights included AnPac’s acquisition of 60% equity interest in Anpai (Shanghai) Health Management Consulting Co. Ltd. as well as continued validation regarding the efficacy of its CDA testing obtained through clinical study follow-ups. The company also completed the development and evaluation of a second-generation cancer detection sensor, launched a joint venture designed to focus on a novel cancer-treatment technology and medical-device development, and filed 261 patent applications globally, among which 150 patents have been granted. AnPac is also continuing to build a proprietary cancer-risk assessment database, which totaled some 244,310 samples as of Sept. 30, 2021. “We are very pleased with our progress in research and development, commercialization, and operational performance for the first nine months in 2021,” said AnPac Bio chair and CEO Dr. Chris Yu in the press release. “We grew revenue by 55.3% and gross margin by 8.8 percentage points. At the same time, we reduced non-GAAP loss by 6.0%. Our number of issued patents, and clinical and commercial sample sizes all reached record high in Q3 2021. We are making solid progress in obtaining regulatory approval for our class III medical device for lung cancer assisting in diagnosis and have also submitted application for registration testing of our multi-cancer detection medical device for 11 types of cancer. We are also working very hard to obtain Laboratory Developed Test (‘LDT’) status for our CDA cancer test in the U.S. Based on our current status and progress, we now expect to obtain registration approval for our class III medical device (for lung cancer assisting in diagnosis) in late 2022.”

To view the full press release, visit https://ibn.fm/Y053A

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 150 issued patents as of Sept. 30, 2021. With two certified clinical laboratories in China and one CLIA- and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation, early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection, based on approximately 43,980 clinical samples as of Sept. 30, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit www.AnPacBio.com

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork